Patents by Inventor Michael Cherry

Michael Cherry has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12019755
    Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events ,organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.
    Type: Grant
    Filed: January 4, 2022
    Date of Patent: June 25, 2024
    Assignee: RiskLens, LLC
    Inventors: Jack Allen Jones, Justin Nicholas Theriot, Jason Michael Cherry
  • Publication number: 20220121754
    Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events ,organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.
    Type: Application
    Filed: January 4, 2022
    Publication date: April 21, 2022
    Applicant: RiskLens, Inc.
    Inventors: Jack Allen Jones, Justin Nicholas Theriot, Jason Michael Cherry
  • Patent number: 11250138
    Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events, organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: February 15, 2022
    Assignee: Risklens, Inc.
    Inventors: Jack Allen Jones, Justin Nicholas Theriot, Jason Michael Cherry
  • Publication number: 20210264034
    Abstract: Systems, methods, and storage media for determining the probability of cyber risk-related loss within one or more computing systems composed of computing elements are disclosed. Exemplary implementations may: assess vulnerability by determining an exposure window for a computing element based on the number of discrete times within a given time frame where the computing element is in a vulnerable state; determine a frequency of contact of the computing element with threat actors; normalize the exposure window and the frequency of contact; calculate a threat event frequency by dividing the normalized exposure window by the normalized frequency of contact; and repeat the steps for multiple elements. When combined with liability data that describes the loss magnitude implications of these events, organizations can prioritize the elements based on loss exposure and take action to prevent loss exposure.
    Type: Application
    Filed: February 26, 2020
    Publication date: August 26, 2021
    Applicant: RiskLens, Inc.
    Inventors: Jack Allen Jones, Justin Nicholas Theriot, Jason Michael Cherry
  • Publication number: 20180373838
    Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.
    Type: Application
    Filed: April 16, 2018
    Publication date: December 27, 2018
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Konrad Karczewski, Michael Snyder, Atul J. Butte, Joel T. Dudley, Eurie Hong, Alan Boyle, J. Michael Cherry, Julie Park
  • Patent number: 9946835
    Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: April 17, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Konrad Karczewski, Michael Snyder, Atul Butte, Joel T. Dudley, Eurie Hong, Alan Boyle, J. Michael Cherry, Julie Park
  • Publication number: 20170337396
    Abstract: A method and apparatus useful to sequester sensitive identifiable data from the data associated therewith and store this sensitive data in a shielded limited access structure while the associated data is periodically processed in a data center while concurrently scanned for potential malware/ransomware script. Once thus cleaned the data processed in the data center is then converted to a read only form and as thus converted brought to the limited access structure where it is screened once again for script tags and if none are found is then merged with the corresponding identifiable data to be printed and mailed. This repeated screening pass together with the periodic nature of the data center's operations combine to minimize all potential exposure to unwanted data contamination while the secured nature of the limited access structure can be used for secure long term storage.
    Type: Application
    Filed: May 20, 2016
    Publication date: November 23, 2017
    Inventors: Michael Cherry, Joseph Kennedy, Manfred Schenk, Mark Switzer
  • Patent number: 9187465
    Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: November 17, 2015
    Assignee: SAREUM LIMITED
    Inventors: John Charles Reader, John Mark Ellard, Helen Boffey, Susanne Taylor, Andrew David Carr, Michael Cherry, Michelle Wilson, Richard Boakye Owoare
  • Patent number: 8921544
    Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    Type: Grant
    Filed: June 3, 2014
    Date of Patent: December 30, 2014
    Assignee: Sareum Limited
    Inventors: John Charles Reader, John Mark Ellard, Helen Boffey, Susanne Taylor, Andrew David Carr, Michael Cherry, Michelle Wilson, Richard Boakye Owoare
  • Patent number: 8618121
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain tricyclic compounds (referred to herein as TC compounds), and especially certain 9H-pyrimido[4,5-b]indole, 9H-pyrido[4?,3?:4,5]pyrrolo[2,3-d]pyridine, and 9H-1,3,6,9-tetraaza-fluorene compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
    Type: Grant
    Filed: July 1, 2008
    Date of Patent: December 31, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: Ian Collins, John Charles Reader, Suki Klair, Jane Scanlon, Glynn Addison, Michael Cherry
  • Patent number: 8530468
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.
    Type: Grant
    Filed: February 19, 2009
    Date of Patent: September 10, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: Ian Collins, John Charles Reader, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Michael Cherry
  • Publication number: 20130116931
    Abstract: Measuring of the binding of a transcription factor (using, for example, chromatin immunoprecipitation) according to the present invention is provides an improved marker for a disease. These markers can be used in diagnostics for diseases where a transcription factor binding event plays a role. Additionally, they can be used to adjust disease risk profiles for healthy individuals as with typical genetic variants.
    Type: Application
    Filed: August 22, 2012
    Publication date: May 9, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Konrad Karczewski, Michael Snyder, Atul J. Butte, Joel T. Dudley, Eurie Hong, Alan Boyle, J. Michael Cherry
  • Patent number: 8378095
    Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    Type: Grant
    Filed: May 9, 2008
    Date of Patent: February 19, 2013
    Assignee: Saruem Limited
    Inventors: John Charles Reader, John Mark Ellard, Michael Cherry
  • Patent number: 8367658
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: February 5, 2013
    Assignee: Cancer Research Technology Limited
    Inventors: Ian Collins, John Charles Reader, Thomas Peter Matthews, Kwai Ming Cheung, Nicolas Proisy, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Glynn Jonathan Addison, Michael Cherry
  • Patent number: 8288425
    Abstract: The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: October 16, 2012
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Michael L. Edwards, Paul J. Cox, Shelley Amendola, Stephanie D. Deprets, Timothy A. Gillespy, Christopher D. Edlin, Andrew D. Morley, Charles J. Gardner, Brian Pedgrift, Herve Bouchard, Didier Babin, Laurence Gauzy, Alain Le-Brun, Tahir N. Majid, John C. Reader, Lloyd J. Payne, Nawaz M. Khan, Michael Cherry
  • Publication number: 20120040967
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds, which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.
    Type: Application
    Filed: September 23, 2011
    Publication date: February 16, 2012
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Ian Collins, John Charles Reader, Thomas Peter Matthews, Kwai Ming Cheung, Nicolas Proisy, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Glynn Jonathan Addison, Michael Cherry
  • Patent number: 8058045
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.
    Type: Grant
    Filed: October 6, 2008
    Date of Patent: November 15, 2011
    Assignee: Cancer Research Technology Limited
    Inventors: Ian Collins, John Charles Reader, Thomas Peter Matthews, Kwai Ming Cheung, Nicolas Proisy, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Glynn Jonathan Addison, Michael Cherry
  • Publication number: 20100331328
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicyclylaryl-aryl-amines compounds of the following formula (referred to herein as BCAA compounds), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc.
    Type: Application
    Filed: February 19, 2009
    Publication date: December 30, 2010
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Ian Collins, John Charles Reader, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Michael Cherry
  • Publication number: 20100311730
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain biarylamine compounds (referred to herein as BAA compounds), and especially certain pyrazin-2-yl-pyridin-2-yl-amine and pyrazine-2-yl-pyrimidin-4-yl-amine compounds of formula (I), which, inter alia, inhibit Checkpoint Kinase 1 (CHK1) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK1 kinase function, and in the treatment of diseases and conditions that are mediated by CHK1, that are ameliorated by the inhibition of CHK1 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionisi?q radiation.
    Type: Application
    Filed: October 6, 2008
    Publication date: December 9, 2010
    Applicant: CANCER RESEARCH TECHNOLOGY LIMITED
    Inventors: Ian Collins, John Charles Reader, Thomas Peter Matthews, Kwai Ming Cheung, Nicolas Proisy, David Hugh Williams, Sukhbinder Singh Klair, Jane Elizabeth Scanlon, Nelly Piton, Glynn Jonathan Addison, Michael Cherry
  • Publication number: 20100298301
    Abstract: The invention provides a compound which is an amide of the formula (1), or a salt, solvate, N-oxide or tautomer thereof; wherein: a is 0 or 1; b is 0 or 1: provided that the sum of a and b is 0 or 1; T is O or NH Ar1 is a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S, and being optionally substituted by one or more substituents R1; Ar2 Js a monocyclic or bicyclic 5- to 10-membered aryl or heteroaryl group containing up to 4 heteroatoms selected from O, N and S and being optionally substituted by one or more substituents R2; and R1 and R2 are as defined in the claims. The compounds are inhibitors of kinases and in particular FLT3, FLT4 and Aurora kinases.
    Type: Application
    Filed: May 9, 2008
    Publication date: November 25, 2010
    Applicant: SAREUM LIMITED
    Inventors: John Charles Reader, John Mark Ellard, Helen Boffey, Susanne Taylor, Andrew David Carr, Michael Cherry, Michelle Wilson, Richard Boakye Owoare